Ascendis Pharma A/S has submitted a Marketing Authorisation Application $(MAA)$ to the European Medicines Agency $(EMA)$ for TransCon CNP (navepegritide) as a treatment for children with achondroplasia. The application is supported by data from three randomized, double-blind, placebo-controlled clinical trials, as well as up to three years of open-label extension data, demonstrating that TransCon CNP was generally well tolerated. In the United States, TransCon CNP is also under priority review by the FDA, with a decision expected by November 30, 2025. No grant or funding from multiple organizations was mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542451-en) on October 08, 2025, and is solely responsible for the information contained therein.